MF101: A multi-component botanical selective estrogen receptor beta modulator for the treatment of menopausal vasomotor symptoms

Expert Opinion on Investigational Drugs

Volumn 21, Issue 7, 2012, Pages 1031-1042

  Leitman, Dale C ^a   Christians, Uwe ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Botanical; Estrogen receptor; Estrogen receptor beta; Hot flash; Menopausal hormone therapy; Menopause; MF101; Vasomotor symptoms

Indexed keywords

CIMICIFUGA RACEMOSA EXTRACT; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HERBACEOUS AGENT; MF 101; PRIMROSE OIL; PROGESTERONE; RALOXIFENE; RED CLOVER EXTRACT; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CIMICIFUGA RACEMOSA; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; FOOD AND DRUG ADMINISTRATION; GENE CONTROL; GENE TARGETING; GENETIC TRANSCRIPTION; HOT FLUSH; HUMAN; LIGAND BINDING; LOOSE FECES; MENOPAUSAL SYNDROME; NERVE CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN CONFORMATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); VAGINA BLEEDING;

CLINICAL TRIALS, PHASE III AS TOPIC; ESTROGEN RECEPTOR BETA; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; PLANT EXTRACTS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; TREATMENT OUTCOME; VASOMOTOR SYSTEM;

EID: 84862287377     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.685652     Document Type: Article

References (74)

1. Hammond CB. Menopause and hormone replacement therapy: an overview. Obstet Gynecol 1996;87(2 Suppl):2S-15S
2. Hall JE. Neuroendocrine changes with reproductive aging in women. Semin Reprod Med 2007;25:344-51 (Pubitemid 47339158)
3. Prior JC. Perimenopause: the complex endocrinology of the menopausal transition. Endocr Rev 1998;19:397-428 (Pubitemid 29116375)
4. Te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002;8:141-54 (Pubitemid 34428965)
5. Morabia A, Costanza MC. International variability in ages at menarche, first livebirth, and menopause. World Health organization collaborative study of neoplasia and steroid contraceptives. Am J Epidemiol 1998;148:1195-205
6. Wood JW. Fecundity and natural fertility in humans. Oxf Rev Reprod Biol 1989;11:61-109
7. Walker ML, Herndon JG. Menopause in nonhuman primates? Biol Reprod 2008;79:398-406
8. Sherman BM, Korenman SG. Hormonal characteristics of the human menstrual cycle throughout reproductive life. J Clin Invest 1975;55:699-706
9. Burger HG, Hale GE, Dennerstein L, Robertson DM. Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause 2008;15(4 Pt 1):603-12
10. Kok HS, van Asselt KM, van der Schouw YT, et al. Genetic studies to identify genes underlying menopausal age. Hum Reprod Update 2005;11:483-93 (Pubitemid 41418803)
11. Arias E, MacDorman MF, Strobino DM, Guyer B. Annual summary of vital statistics-2002. Pediatrics 2003;112(6 Pt 1):1215-30
12. Wallis J. A survey of reproductive parameters in the free-ranging chimpanzees of Gombe National Park. J Reprod Fertil Suppl 1997;109:297-307
13. Margulis SW, Atsalis S, Bellem A, Wielebnowski N. Assessment of reproductive behavior and hormonal cycles in geriatric western lowland gorillas. Zoo Biol 2007;26:117-39 (Pubitemid 46775624)
14. Bronikowski AM, Alberts SC, Altmann J, et al. The aging baboon: comparative demography in a non-human primate. Proc Natl Acad Sci USA 2002;99:9591-5 (Pubitemid 34764657)
15. Martin LJ, Carey KD, Comuzzie AG. Variation in menstrual cycle length and cessation of menstruation in captive raised baboons. Mech Ageing Dev 2003;124:865-71 (Pubitemid 37130136)
16. Albertazzi P. Noradrenergic and serotonergic modulation to treat vasomotor symptoms. J Br Menopause Soc 2006;12(1):7-11 (Pubitemid 43349416)
17. Albertazzi P. A review of non-hormonal options for the relief of menopausal symptoms. Treat Endocrinol 2006;5:101-13
18. Carpenter JS, Gilchrist JM, Chen K, et al. Hot flashes, core body temperature, and metabolic parameters in breast cancer survivors. Menopause 2004;11:375-81 (Pubitemid 40362161)
19. Freedman RR. Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril 1998;70:332-7 (Pubitemid 28361490)
20. Freedman RR. Core body temperature variation in symptomatic and asymptomatic postmenopausal women: brief report. Menopause 2002;9:399-401 (Pubitemid 36706333)
21. Freedman RR, Norton D, Woodward S, Cornelissen G. Core body temperature and circadian rhythm of hot flashes in menopausal women. J Clin Endocrinol Metab 1995;80:2354-8
22. Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Womens Ment Health 2007;10:247-57
23. Molnar GW. Body temperatures during menopausal hot flashes. J Appl Physiol 1975;38:499-503
24. Kronenberg F. Hot flashes: epidemiology and physiology. Ann NY Acad Sci 1990;592:52-86 (Pubitemid 20273207)
25. Koutsilieris M, Tolis G. Gonadotropin-releasing hormone agonistic analogues in the treatment of advanced prostatic carcinoma. Prostate 1983;4:569-77 (Pubitemid 14243322)
26. Files JA, Ko MG, Pruthi S. Managing aromatase inhibitors in breast cancer survivors: not just for oncologists. Mayo Clin Proc 2010;85:560-6
27. Rand KL, Otte JL, Flockhart D, et al. Modeling hot flushes and quality of life in breast cancer survivors. Climacteric 2011;14:171-80
28. Aziz NA, Heyns CF. Evaluation of core and surface body temperatures, prevalence, onset, duration and severity of hot flashes in men after bilateral orchidectomy for prostate cancer. Int Braz J Urol 2008;34:15-20
29. Thurston RC, Christie IC, Matthews KA. Hot flashes and cardiac vagal control during women's daily lives. Menopause 2012;19:406-12
30. Hautamaki H, Piirila P, Haapalahti P, et al. Cardiovascular autonomic responsiveness in postmenopausal women with and without hot flushes. Maturitas 2011;68:368-73
31. Freedman RR, Woodward S, Sabharwal SC. Alpha 2-adrenergic mechanism in menopausal hot flushes. Obstet Gynecol 1990;76:573-8 (Pubitemid 20322054)
32. Dormire SL. The potential role of glucose transport changes in hot flash physiology: a hypothesis. Biol Res Nurs 2009;10:241-7
33. Sturdee DW. The menopausal hot flush-anything new? Maturitas 2008;60:42-9
34. Vilar-Gonzalez S, Perez-Rozos A, Cabanillas-Farpon R. Mechanism of hot flashes. Clin Transl Oncol 2011;13:143-7
35. Thurston RC, El Khoudary SR, Sutton-Tyrrell K, et al. Are vasomotor symptoms associated with alterations in hemostatic and inflammatory markers? findings from the Study of Women's Health Across the Nation. Menopause 2011;18:1044-51
36. Ozkaya E, Cakir E, Kara F, et al. Impact of hot flashes and night sweats on arotid intima-media thickness and bone mineral density among postmenopausal women. Int J Gynaecol Obstet 2011;113(3):235-8
37. Emond JA, Patterson RE, Natarajan L, et al. Sex hormone concentrations and the risk of breast cancer recurrence in postmenopausal women without hot flashes. Cancer Epidemiol Biomarkers Prev 2011;20:939-45
38. Huang Y, Malone KE, Cushing-Haugen KL, et al. Relationship between menopausal symptoms and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 2011;20:379-88
39. Writing Group for Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
40. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95(Suppl 1):s1-s66.
41. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12 (Pubitemid 38489892)
42. Tsai SA, Stefanick ML, Stafford RS. Trends in menopausal hormone therapy use of US office-based physicians, 2000-2009. Menopause 2011;18:385-92
43. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007;356:1670-4 (Pubitemid 46631679)
44. Glass AG, Lacey JV Jr, Carreon JD, et al. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007;99:1152-61 (Pubitemid 47233065)
45. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008;107:427-30 (Pubitemid 351172118)
46. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007;9:R28
47. Eisenberg DM, Kessler RC, Van Rompay MI, et al. Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 2001;135:344-51 (Pubitemid 32823241)
48. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-75 (Pubitemid 28520643)
49. Gold EB, Bair Y, Zhang G, et al. Cross-sectional analysis of specific complementary and alternative medicine (CAM) use by racial/ethnic group and menopausal status: the Study of Women's Health Across the Nation (SWAN). Menopause 2007;14:612-23 (Pubitemid 47051953)
50. Mahady GB, Parrot J, Lee C, et al. Botanical dietary supplement use in peri-and postmenopausal women. Menopause 2003;10:65-72 (Pubitemid 36706324)
51. Bair YA, Gold EB, Zhang G, et al. Use of complementary and alternative medicine during the menopause transition: longitudinal results from the Study of Women's Health Across the Nation. Menopause 2008;15:32-43
52. Cvoro A, Paruthiyil S, Jones JO, et al. Selective activation of estrogen receptor-beta transcriptional pathways by an herbal extract. Endocrinology 2007;148:538-47. (Pubitemid 46150775)
53. Mersereau JE, Levy N, Staub RE, et al. Liquiritigenin is a plant-derived highly selective estrogen receptor beta agonist. Mol Cell Endocrinol 2008;283:49-57
54. Evans RM. The steroid and thyroid hormone receptor superfamily. Science (New York, NY) 1988;240:889-95
55. Webb P, Lopez GN, Uht RM, et al. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443-56
56. Feng W, Ribeiro RC, Wagner RL, et al. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998;280:1747-9 (Pubitemid 28283497)
57. McKenna NJ, Lanz RB, O'Malley BW. Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 1999;20:321-44 (Pubitemid 30649811)
58. An J, Ribeiro RC, Webb P, et al. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc Natl Acad Sci USA 1999;96:15161-6 (Pubitemid 30019782)
59. Couse JF, Korach KS. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 1999;20:358-417 (Pubitemid 30654784)
60. Krege JH, Hodgin JB, Couse JF, et al. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci USA 1998;95:15677-82 (Pubitemid 29018759)
61. Lonard DM, Lanz RB, O'Malley BW. Nuclear receptor coregulators and human disease. Endocr Rev 2007;28:575-87 (Pubitemid 47236337)
62. Hammes SR, Levin ER. Minireview: recent advances in extranuclear steroid receptor actions. Endocrinology 2011;152:4489-95
63. Hammes SR, Levin ER. Extranuclear steroid receptors: nature and actions. Endocr Rev 2007;28:726-41 (Pubitemid 350294293)
64. Paruthiyil S, Cvoro A, Zhao X, et al. Drug and cell type-specific regulation of genes with different classes of estrogen receptor beta-selective agonists. PloS One 2009;4:e6271.
65. Harris HA, Katzenellenbogen JA, Katzenellenbogen BS. Characterization of the biological roles of the estrogen receptors, ERalpha and ERbeta, in estrogen target tissues in vivo through the use of an ERalpha-selective ligand. Endocrinology 2002;143:4172-7 (Pubitemid 35239546)
66. Minutolo F, Macchia M, Katzenellenbogen BS, et al. Estrogen receptor beta ligands: recent advances and biomedical applications. Med Res Rev 2011;31:364-442
67. Paruthiyil S, Parmar H, Kerekatte V, et al. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004;64:423-8. (Pubitemid 38114127)
68. Zhang L, Blackman BE, Schonemann MD, et al. Estrogen receptor beta-selective agonists stimulate calcium oscillations in human and mouse embryonic stem cell-derived neurons. PloS One 2010;5:e11791.
69. Kupfer R, Swanson L, Chow S, et al. Oxidative in vitro metabolism of liquiritigenin, a bioactive compound isolated from the Chinese herbal selective estrogen beta-receptor agonist MF101. Drug Metab Dispos 2008;36:2261-9
70. Grady D, Sawaya GF, Johnson KC, et al. MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trial. Menopause 2009;16:458-65.
71. Tagliaferri M, Creasman J, Caygill KA, et al. Clinically meaningful efficacy of a non-estrogen agent: re-analysis of phase-2 data evaluating MF101. Climacteric 2012. [Epub ahead of print].
72. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007;87:905-31 (Pubitemid 47084672)
73. Shughrue PJ, Askew GR, Dellovade TL, et al. Estrogen-binding sites and their functional capacity in estrogen receptor double knockout mouse brain. Endocrinology 2002;143:1643-50 (Pubitemid 34415878)
74. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause 2000;7:310-17